1887
Volume 2023, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Introduction: Methotrexate (MTX) is a folic acid antagonist used to treat different immunological or proliferative illnesses because of its anti-proliferative and anti-inflammatory effects. MTX Toxicity is considered a severe problem. Although acute toxicity related to high-dose administration (doses ≥500 mg/m2) can be predicted based on the given dose, chronic toxicity still has no specific factors to predict it, so treatment depends on the history and symptoms of toxicity. MTX was initially used for oncology indications with high cyclic doses, then expanded to non-oncology indications with different low doses and frequencies. This significant change in doses resulted in dosing errors that contributed to MTX toxicity reports. Measures to prevent the toxicity of MTX should be implemented.

Case: A 66-year-old female patient ingested 10 mg of MTX daily for one month instead of the once-toxicity symptoms. The serum level of MTX was requested, and treatment with folinic acid was initiated until the patient improved with the discontinuation of MTX.

Discussion: There is limited literature about the lack the total cumulative dose, duration of intake, or serum level of MTX. All this information was provided in this case report, but drug-drug interactions were not reviewed, although aspirin and pantoprazole were identified as having interactions with methotrexate in this patient. Minimum total cumulative dose identification may help assess the toxicity risk in such patients.

Conclusion: Low-dose MTX chronic toxicity still needs further information to guide the patient’s risk of toxicity and when to initiate treatment. Safety-practical measures should be implemented to prevent such administration errors.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2023.31
2023-11-13
2024-07-14
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2023/4/qmj.2023.31.html?itemId=/content/journals/10.5339/qmj.2023.31&mimeType=html&fmt=ahah

References

  1. Koźmiński P, Halik PK, Chesori R, Gniazdowska E. Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies, and cancers. International Journal of Molecular Sciences. 2020;21:(10):3483. doi:10.3390/ijms21103483.
    [Google Scholar]
  2. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al.. Methotrexate is an old drug with new tricks. International Journal of Molecular Sciences. 2019;20:(20):5023. doi:10.3390/ijms20205023.
    [Google Scholar]
  3. Zaiwei S, Hu Y, Liu S, Wang G, Zhai S-D, Zhang X, et al.. Medication therapy of high-dose methotrexate: An evidence-based practice guideline division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. 2021; doi:10.22541/au.162273784.44372285/v1.
    [Google Scholar]
  4. Dhingra H, Jadhav A, Kalra M, Mahajan A. Safe administration of high dose methotrexate with minimal drug level monitoring-experience from a center in North India. Pediatric Hematology Oncology Journal. 2017;2:(2). doi:10.1016/j. phoj.2017.11.137.
    [Google Scholar]
  5. García-González CM, Baker J. Treatment of early rheumatoid arthritis: Methotrexate and beyond. Current Opinion in Pharmacology. 2022;64::102227. doi:10.1016/j. coph.2022.102227.
    [Google Scholar]
  6. Ahmadzadeh A, Zamani N, Hassanian-Moghaddam H, Hadeiy SK, Parhizgar P. Acute versus chronic methotrexate poisoning; a cross-sectional study. BMC Pharmacology and Toxicology. 2019;20:(1). doi:10.1186/s40360-019-0316-8.
    [Google Scholar]
  7. Raghavendra S, Khurrana T, Malhotra AK. Yet another case of acute methotrexate toxicity due to accidental overdose. Journal of the Association of Physicians of India. 2020;68:(1):69.
    [Google Scholar]
  8. Nimkar SV, Yelne P, Gaidhane S, Acharya S, Kumar S. Fatal manifestations of methotrexate overdose in case of psoriasis due to dosing error. Cureus. 2022; doi:10.7759/cureus.30041.
    [Google Scholar]
  9. Sajith M, Pawar A, Bafna V, Bartakke S, Subramanian K, Vaidya N. Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with Acute Lymphoblastic Leukaemia (all). Indian Journal of Hematology and Blood Transfusion. 2019;36:(1):51–8. doi:10.1007/ s12288-019-01144-3.
    [Google Scholar]
  10. Bergner R, Wadsack D, Löffler C. Severe MTX toxicity in rheumatic diseases - analysis of 22 cases. Journal of Rheumatic Diseases and Treatment. 2019;5:(1). doi:10.23937/2469-5726/1510070.
    [Google Scholar]
  11. Yajima N, Kawaguchi T, Takahashi R, Nishiwaki H, Toyoshima Y, Oh K, et al.. Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: A Multicenter cross-sectional study. 2022; doi:10.1101/2022.08.24.22279163.
    [Google Scholar]
  12. Jiang R, Mei S, Zhao Z. Leucovorin (folinic acid) rescue for high-dose methotrexate: A Review. Journal of Clinical Pharmacy and Therapeutics. 2022;47:(9):1452–60. doi:10.1111/jcpt.13739.
    [Google Scholar]
  13. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine. 1977;297:(12):630–4. doi:10.1056/nejm197709222971203.
    [Google Scholar]
  14. Evans William E, Pratt Charles B, Taylor RH, Larry F, Crom William R. Pharmacokinetic monitoring of high-dose methotrexate. Cancer Chemotherapy and Pharmacology. 1979;3:(3). doi:10.1007/bf00262416.
    [Google Scholar]
  15. Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: A cohort of 28 patients. Autoimmunity Reviews. 2014;13:(11):1109–13. doi:10.1016/j. autrev.2014.08.027.
    [Google Scholar]
  16. Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al.. Overview of methotrexate toxicity: A comprehensive literature review. Cureus. 2022; doi:10.7759/cureus.29518.
    [Google Scholar]
  17. Campbell JM, Bateman E, Stephenson MD, Bowen JM, Keefe DM, Peters MD. Methotrexate-induced toxicity pharmacogenetics: An umbrella review of systematic reviews and meta-analyses. Cancer Chemotherapy and Pharmacology. 2016;78:(1):27– 39. doi:10.1007/s00280-016-3043-5.
    [Google Scholar]
  18. Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, et al.. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121:(26):5145–53. doi:10.1182/blood-2013-01-480335.
    [Google Scholar]
  19. Bidaki R, Kian M, Owliaey H, Babaei Zarch M, Feysal M. Accidental Chronic Poisoning with Methotrexate; Report of Two Cases. Emerg (Tehran). 2017;5:(1):67.. PMID: 28894782; PMCID: PMC5585837
    [Google Scholar]
  20. Thompson JA, Love JS, Hendrickson RG. Methotrexate toxicity from unintentional dosing errors: Calls to a poison center and death descriptions. The Journal of the American Board of Family Medicine. 2021;34:(6):1246–8. doi:10.3122/jabfm.2021.06.210120.
    [Google Scholar]
  21. Call to action: Longstanding strategies to prevent accidental daily methotrexate dosing must be implemented [Internet]. 2019 [cited 2023 Nov 1]. Available from: https://www.ismp.org/resources/call-action-longstanding-strategies-prevent-accidental-daily-methotrexate-dosing-must-be.
/content/journals/10.5339/qmj.2023.31
Loading
  • Article Type: Research Article
Keyword(s): case reportsleucovorinmethotrexateoverdoseserum level and toxicity
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error